CoChat

Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma

Open access
Xue, Li‐Jun, Mao, Xiao‐Bei, Ren, Li‐Li, Chu, Xiao‐Yuan · 2017 · Cancer Medicine
Cited by 82

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The whole outcome for patients with gastric carcinoma (GC) is very poor because most of them remain metastatic disease during survival even at diagnosis or after surgery. Despite many improvements in multiple strategies of chemotherapy, immunotherapy, and targeted therapy, exploration of novel alternative therapeutic targets is still warranted. Chemokine receptor 4 (CXCR 4) and its chemokine ligand 12 (CXCL 12) have been identified with significantly elevated levels in various malignancies including GC, which correlates with the survival, proliferation, angiogenesis, and metastasis of tumor cells. Increasing experimental evidence suggests an implication of inhibition of CXCL 12/CXCR 4 axis as a promising targeted therapy, although there are rare trials focused on the therapeutic efficacy of CXCR 4 inhibitors in GC until recently. Therefore, it is reasonable to infer that specific antagonists or antibodies targeting CXCL 12/CXCR 4 axis alone or combined with chemotherapy will be effective and worthy of further translational studies as a potential treatment strategy in advanced GC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.1085

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 82

Metadata

Authors
Xue, L., Mao, X., Ren, L., & Chu, X.
Venue
Cancer Medicine
Publisher
Wiley
Published
2017-05-23
Volume
6
Issue
6
Pages
1424-1436
ISSN
2045-7634 (ISSN-L)
OpenAlex
W2617400421
Cited by
82
References
1
FWCI
3.99
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. https://app.cochat.ai/papers/10.1002/cam4.1085
The paper
Xue, L., Mao, X., Ren, L., & Chu, X. (2017). Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.1085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.